2I9I2016
`
`EM-‘— L SlC>'HU F’
`
`10 Worst Drug Launches | MD Magazine
`
`l'Iz_v.s‘ici¢zn!s'
`
`i W All Specialties
`
`G-1|-incur-1-rind .-
`Nucaiuml
`
`SMIVIIOI EUEIWIIE
`LEARN MORE
`llIIW.ld“RLLC.
`EVERY SOMEDAY NE DS A PLAN?’
`raaiyamengesen-ca.
`IhnO—ON5f SDC in SD15
`noon! u
`We'll help you live the life you want with free retirement guidance.
`
`
`rinLi.c.An¢mmm.a
`
`
`
`
`Physician's Money Digest‘
`Personal Finance
`
`Investing
`
`
`
`
`
`Multiple Sclerosis
`
`Condition Center
`Contributors
`Columns
`Learn More
`
`
`Most Popular
`
`Why I Became A Concierge Medicine
`Doctor
`
`Dr. Reddy's Anti—Psoriasis Spray Gets
`FDA Nod
`
`Q8-A: Corrimon Misconceptions About
`Psoriatic Arthritis
`
`The PMD Critical List: An Uber for
`Healthcare?
`
`Should We Cap Hospital CEO Salaries?
`
` mGm°
`
`Putting finance into practice for physicians
`
`Cll(l( hereto visit
`
`
`
`Latest PMD News
`
`How Much Did You REALLY Lose in the
`Stock Market?
`
`Federal Student Loan Repayment: Know
`Your Options (Part 1)
`
`For Valentine's Day, Love Your Spouse
`or Partner, Not Your ‘Big Idea’
`
`Healthcare Entities Recognize the Value
`of Cybersecurity
`
`4 Can't~Miss Stops on Southwest
`Germany's Beer Trail
`
`10 Worst Drug Launches
`in
`
`All Specialties
`
`
`News
`
`Conferences
`
`Comment(0)
`
`Practice Management
`Lifestyle
`Columns
`Contributors
`
`Related Tags
`Practice Managemem >
`
`With the patent ciff, growing research costs and increasing trial timelines,
`there are plenty of risks associated with pharmaceutical drug research and
`
`development. And yet, once a company has approval, the risks don't stop.
`
`Although only a small percentage of experimental therapies actually get
`
`approved, these drugs still face the risk of a failed drug launch. There have
`
`been plenty of bbckbuster drugs wi h solid hits, but there have also been the
`
`Provenges.
`
`Now that the patent cliff has hit, many phannaceutical companies have large
`
`pipelines so they can build up franchises again. They would do well to learn
`
`from previous missteps. FiercePharma isted its top 10 drug launch disasters.
`
`The majority are pricey cancer drugs hat payors balked at paying for.
`
`Here are the top five.
`
`5. Horizant
`
`Company: Xenoport
`
`OonditionIDisease: restless leg syndrome
`
`Sales: $1.6 million in the third quarter of 2012
`
`Unlike the rest of the top five, l-lorizant's trouble didn't stem from cost. Instead,
`
`it was the partnership between GlaxoSrnithK|ine and XenoPort. When sales
`
`were much lower han expected the two companies turned on each other
`
`before finally going their separate ways.
`
`4. Benlysta
`
`Company: Human Genome Sciences
`
`ConditionIDisease: lupus
`Sales: 559 million in 2011
`
`Price: $35,000 for a year of treatment
`
`One problem was that physicians were hesitant to prescribe the drug because
`
`of the cost and the feat that they would be on the hook until reimbursement
`
`came hrough.
`
`tttpflwww ltplive.canIptysidas-mmey-dgesVp'a1ice-maaganerfl10-wast-d'ug-lanches
`
`Page 1 of 3
`
`SENJU EXHIBIT 2308 1
`LUPIN v. SENJU
`
`/'3
`
`IPR2015—01099
`
`

`
`2l9fZ)16
`
`10 Worst Drug Lancles | MD Magazine
`
`3. Zaltrap
`
`Company: Sanofi
`ConditionIDisease: oolorectal cancer
`
`Sales: 7 million euros in the third quarter of 2012
`Price: $9,600 a month
`
`Sanofi had a second drug in the top 10, so it's familiar with development risk.
`
`The problem with Zaltrap was that it was quite expensive, Providers didn't like
`
`that there were less expensive altematives that were just as good.
`
`2. Provenge
`
`Company: Dendreon
`
`OonditionIDisease: prostate cancer
`Sales: $228 million in 2011
`
`Price: $93,000 for the treatment
`
`While Provenge's sales weren't bad, they fell far short of Dendreon's forecast
`
`of $350 million. Plus, Johnson 8. Johnson's Zytiga has become a popular
`
`alternative. Although, Zytiga is approved for use after chemotherapy fails,
`
`physicians have been prescribing it for off—|abe| use in earlier stages of he
`
`disease, causing J&J's drug to increase market share, while Provenge's
`
`stagnated. Lastly, onoology drugs always have large price tags and physicians
`were concerned about reimbursements‘
`
`1. Makena
`
`Company: K—V Pharmaceuticals
`
`Condition/Disease: preventing premature bir h
`
`Sales: $5.1 million in revenue for he final quarter of 2011
`Price: $1,500 a dose
`
`Overall the cost for a full course of treatment is $30,000, yet a string of
`
`compounding pharmacies were already making this therapy for a lot cheaper
`
`—just $10 to $20 a dose,
`
`To see the full list and more about the dmgs, click here.
`
`Comment (0)
`
`Multiple Sclerosis Condition Center .
`
`CONFERENCES >
`
`CONTRIBUTORS >
`
`MJH Associates >
`
`Resources
`
`PHY$lClAN'S MONEY DIGEST >
`
`V|DEOS>
`
`JOURNALS>
`
`mpjlwww hcplive.canlplIysicians-mmey~dgesVpractice-maragemerl/10-worst-(tug-lanches
`
`213
`
`Page 2 of 3
`
`

`
`2/9/2016
`
`10 Worst Drug Launches | MD Magazine
`
`Insights
` Resources
`Practice Brief
`
`Affordable Care Act
`
`Military Medicine
`
`Personal Finance
`
`Investing
`
`Retirement
`
`Practice Management
`
`Lifestyle
`
`Columns
`
`ONCLive
`
`OTCGuide
`
`Pharmacy Times
`
`RareDR
`
`Contact Us
`
`Press Release
`
`Privacy Policy
`
`Staff
`
`Specialty Pharmacy Times
`
`Terms & Conditions
`
`Targeted Oncology
`
`Copyright MD Magazine 2006-
`
`2015 Intellisphere, LLC. All
`
`Rights Reserved.
`
`http://www hcplive.com/physicians-money-digest/practice-management/10-worst-drug-launches
`
`3/3
`
`Page 3 of 3